In particular, the success of ICIs, represented by PD-1/PD-L1 mAbs, and of ACT, represented by chimeric antigen receptor T (CAR-T) cell therapy, in the field of anti-tumor therapy represents a new stage in tumor immunotherapy. The gene discussed is CD274; the disease is neoplasm.